Please login to the form below

Not currently logged in
Email:
Password:

Mundipharma appoints Paul Medeiros head of corporate and business development

He joins from AVI BioPharma and will lead Mundipharma's corporate growth across Europe

Paul Medeiros - MundipharmaAVI BioPharma's Paul Medeiros has joined Mundipharma as head of corporate and business development.

Medeiros will also join the executive leadership team at the UK-based group, which controls Napp in the UK and has associated companies in 32 other European countries.

His role will be to extend and expand areas for growth within this European network of companies.

“Paul's deep experience and network in the pharma industry, combined with his entrepreneurial mind-set and nuanced understanding of the business, will be essential for Mundipharma's continued growth,” said Antony Mattessich, regional director at Mundipharma Europe.

Medeiros was most recently senior VP and chief business officer at AVI BioPharma, a company focused on the development of RNA-based therapeutics for rare diseases.

Other roles in his 19-year career in the biopharma industry include VP, global licensing and strategic alliances for Schering-Plough, as well as several positions in sales and marketing at Merck & Co.

He has been involved with licensing and strategic partnering initiatives in specialist therapy areas, as well as technology acquisitions.

9th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...